FDA seeks input on rare-disease drug-development framework
FDA’s October 14 announcement launches a rare-disease framework initiative and lists an October 28 meeting to hear from patients, advocates, industry and others.
What the record says
The initiative will consider how drug and biologic development can account for disease differences, patient needs and evidence from small populations. FDA says the October 28 meeting will be held at its White Oak campus with facilitation by the Reagan-Udall Foundation. The agency plans additional roundtables and requests for information to inform future guidance, possible regulatory revisions and staff training.
Source details and supporting locations.
Practical next step
Review FDA’s announcement and official participation materials if you want to provide input.
Limits and what is not established
This is a framework-development and feedback process, not approval of a therapy or proof that approval standards have already changed. This source alone does not establish a comment deadline or individual meeting registration.
Sources checked October 17, 2026. Later notices may change instructions or arrangements.
Original sources
U.S. Food and Drug Administration: original information